https://www.selleckchem.com/products/bi-3406.html
Subgroup analyses revealed that JKAP level during ETN therapy was increased in W24 response patients, while no difference was discovered in JKAP level among different time points in W24 non-response patients. Meanwhile, JKAP level during ETN treatment was elevated in both W24 remission patients and W24 non-remission patients, however, its increment was more evident in W24 remission patients. JKAP correlates with reduced disease risk and inflammation, and its increment during ETN treatment associates with commendable treatment efficiency